Martínez-Cornelio A, González-Pérez J, Tabares-García FJ, Ramos-Salgado F, Alvarado-Cabrero I, Hernández-Toriz

Language: Spanish
References: 25
Page: 293-299
PDF size: 135.98 Kb.

ABSTRACT

Background: Prostatic neuroendocrine carcinomas comprise ‹1% of all prostate neoplasms, and ~200 cases have been reported in the literature. We undertook this study to describe the experience in the management of prostatic neuroendocrine carcinoma with androgen-deprivation therapy (ADT). Methods: We designed a retrospective, descriptive and observational study. In patients with suspicion of prostate cancer, transrectal ultrasonography-guided biopsy (TRUS) or transurethral resection of prostate (TURP) was carried out during the period from January 2000 to December 2007. Patients were selected by anatomopathological diagnostic study of neuroendocrine carcinoma including pure and mixed variants. Characteristics analyzed were age, clinical stage, prostatespecific antigen (PSA), imaging studies, treatment and survival. Results: Ten cases were included with a median age of 66.5 years. Symptoms at diagnosis were associated with metastasis to other organs, one with bone metastasis, and prese nting pain in 100% of the cases. A suspicious rectal digital examination was detected in 100% of the patients. In three (30%) patients, PSA was suspicious for prostate cancer. The extension studies showed bone, locoregional, lung and hepatic metastases. In six (60%) patients mixed variant was documented (acinar adenocarcinoma and neuroendocrine carcinoma) with a median survival of 11.6 months. In four patients (40%), pure neuroendocrine carcinoma was documented with a median survival of 7 months. Conclusions: Prostatic neuroendocrine carcinoma is uncommon, aggressive and represents a prostatic neoplasia without PSA expression. In advanced disease, very low response is reached with ADT.

REFERENCES

1. Catalona WJ. Management of cancer of the prostate. N Engl J Med 1994;331:996-1004.

2. Novak J, Hanus T, Dvoracek J. Small-cell carcinoma of the prostate. Cas Lek Cesk 1998;137:522-524.

3. Nadig SN, Deibler AR, El Salomony TM, Hull GW, Bissada NK. Small cell carcinoma of the prostate: an underrecognized entity. Can J Urol 2001;8:1207-1210.

4. Sakai H, Tsuruta T, Wajiki M, Small cell carcinoma of the prostate: a case report. Hinyokika Kiyo 2004;50:269-271.

5. Patel A, Ball J, Cahappell M. Pure small cell carcinoma of the prostate. Br J Urol 1993;72:380-381.

6. Bonkhoff H, Wernert N, Dhom G, Remberger K. Relation of endocrineparacrine cells to cell proliferation in normal, hyperplastic and neoplasic human prostate. Prostate 1991;19:91-98.

7. Jiménez R, Ochoa C. First National Consensus Meeting on T3 Prostate Cancer Management. Gamo 2005;4:36-38.

8. Partin AW, Steinberg GD, Pitcock RV, Wu L, Piantadosi S, Coffey DS, et al. Use of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease free survival among patients with prostate cancer. Cancer 1992;70:161-168.

9. Di Sant’Agnese PA, Cockett AT. The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research. J Urol 1994;152(5 Pt 2):1927-1931.

10. Oesterling JE, Hauzeur CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: a clinical pathological and immunohistological study of 27 patients. J Urol 1992;147(3 Pt 2):804-807.

11. Alapont J, Montaner M, Pontones J. Carcinoma prostático de células pequeñas. Acta Urol Esp 2002;26:585-588.

12. Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Voria G, et al. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate 2003;55:168-179.

13. Kadmon D, Thompson TC, Lynch GR, Scardino PT. Elevated plasma chromogranin A concentrations in prostatic carcinoma. J Urol 1991;146: 358-361.

14. Sarma DP, Weilbaecher TG. Small-cell carcinoma of the prostate. Urology 1989;33:332-335.

15. Aygun C. Small cell carcinoma of the prostate: a case report and review of the literature. Md Med J 1997;46:353-356.

16. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008;32:65-70.

17. Ro JY, Tetu B, Ayala AG, Ordóñez NG. Small cell carcinoma of the prostate. II: Immunohistochemical and electron microscopic studies of 18 cases. Cancer 1987;59:977-982.

18. Tetu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordóñez NG. Small cell carcinoma of the prostate. I: A clinicopathologic study of 20 cases. Cancer 1987;59:1803-1809.

19. Di Sant’Agnese PA, Abraham TK. Neuroendocrine differentiation in prostatic malignancy. Cancer 1996;78:357-361.

20. Wu JT, Astill ME, Liu GH, Stephenson RA. Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients. J Clin Lab Anal 1998;12:20-25.

21. Jiborn T, Bjartell A, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 1998;51:585-589.

22. Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 1999;6:503-519.

23. Pinski J, Halmos G, Schally AV. Somatostatin analog RC-160 and bombesin/ gastrin releasing peptide antagonist RC-3095 inhibit the growth of androgen independent DU-145 human prostate cancer line in nude mice. Cancer Lett 1993;71:189-196.

24. Di Silverio F, Sciarra A. Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin. A in patients with androgen ablation refractory prostate cancer. J Urol 2003;170:1812-1816.

25. Dimopoulos MA, Kiamouris C, Gika D, Deliveliotis C, Giannopoulos A, Zervas A, et al. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study. Urology 2004;63:120-125.